Orwin John A

SEC source: 0001415889-24-012849 · form4-05102024_040541.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2034-05-07

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001415889-24-012849 · form4-05102024_040541.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,875

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001415889-24-011059 · form4-04172024_110421.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1

F1 · shares: On April 11, 2024, the Reporting Person purchased directly from the Issuer one share of the Issuer's Series A Junior Preferred Stock, par value $0.0001 per share, for a purchase price of $0.01 pursuant to a Stock Purchase Agreement, dated as of April 11, 2024, by and between the Reporting Person and the Issuer.

SEC source: 0001209191-24-001049 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,030

Underlying: Common Stock · 6,030 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-24-001049 · doc4.xml · derivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,510

Underlying: Common Stock · 16,510 shares

Expires 2034-01-02

F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 11

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 2,044 shares

Expires not disclosed

F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 10

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 3,676 shares

Expires 2032-05-13

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 9

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 3,462 shares

Expires 2031-05-14

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 8

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 3,171 shares

Expires 2030-05-15

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 7

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 7,038 shares

Expires 2029-05-20

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 6

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 9,260 shares

Expires 2028-05-18

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 5

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 9,260 shares

Expires 2027-05-19

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 4

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 9,260 shares

Expires 2026-05-20

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 3

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 9,260 shares

Expires 2025-05-15

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 12,500 shares

Expires 2024-01-10

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.

SEC source: 0000950170-23-070863 · ownership.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F1 · shares: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F1 · price: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").

SEC source: 0001610717-23-000347 · form4.xml · derivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-11-08

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from November 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

SEC source: 0001209191-23-049806 · doc4.xml · derivative · entry 4

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,900

Underlying: Common Stock · 3,900 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F5 · derivative.exercise_date: The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date.

F5 · derivative.expiration_date: The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date.

SEC source: 0001209191-23-049806 · doc4.xml · derivative · entry 3

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,035

Underlying: Common Stock · 2,035 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F4 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F4 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-23-049806 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,600

Underlying: Common Stock · 10,600 shares

Expires 2033-09-14

F2 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on October 15, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-23-049806 · doc4.xml · derivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,311

Underlying: Common Stock · 3,311 shares

Expires 2033-09-14

F1 · derivative.exercise_date: The stock option vests as of 1/4 of the total shares monthly beginning on October 6, 2023 and each month thereafter until fully vested on January 6, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001415889-24-010243 · form4-04042024_010411.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,541

F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001203311-23-000061 · edgardoc.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,047

F1 · security: These securities are restricted stock units and will be settled in common stock upon vesting.

F2 · shares: These restricted stock units shall vest in full on May 31, 2024.

F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0001209191-23-030956 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2033-05-16

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-23-030956 · doc4.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,375

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-23-008958 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,000

Underlying: Class A Common Stock · 435,000 shares

Expires 2033-02-08

F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from January 1, 2023. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001209191-22-050778 · doc4.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,492

F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" and does not represent a discretionary trade by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.83 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-037114 · doc4.xml · derivative · entry 8

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 58,995 shares

Expires 2028-11-14

F5 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 11/15/2018. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001209191-22-037114 · doc4.xml · derivative · entry 7

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,995

Underlying: Class A Common Stock · 58,995 shares

Expires 2028-11-14

F2 · price: The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the "Option Repricing"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022. Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option. The Option Repricing does not apply to options held by non-employee directors of the Issuer.

F5 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 11/15/2018. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001209191-22-037114 · doc4.xml · derivative · entry 6

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 148,754 shares

Expires 2028-10-29

F4 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 10/1/2018. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001209191-22-037114 · doc4.xml · derivative · entry 5

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,754

Underlying: Class A Common Stock · 148,754 shares

Expires 2028-10-29

F2 · price: The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the "Option Repricing"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022. Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option. The Option Repricing does not apply to options held by non-employee directors of the Issuer.

F4 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 10/1/2018. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001209191-22-037114 · doc4.xml · derivative · entry 4

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 241,000 shares

Expires 2030-02-25

F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 1/1/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001209191-22-037114 · doc4.xml · derivative · entry 3

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,000

Underlying: Class A Common Stock · 241,000 shares

Expires 2030-02-25

F2 · price: The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the "Option Repricing"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022. Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option. The Option Repricing does not apply to options held by non-employee directors of the Issuer.

F3 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 1/1/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001209191-22-037114 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 260,000 shares

Expires 2031-01-26

F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001209191-22-037114 · doc4.xml · derivative · entry 1

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,000

Underlying: Class A Common Stock · 260,000 shares

Expires 2031-01-26

F2 · price: The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the "Option Repricing"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022. Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option. The Option Repricing does not apply to options held by non-employee directors of the Issuer.

F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0000899243-22-018465 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,676

Underlying: Common Stock · 3,676 shares

Expires 2032-05-13

SEC source: 0000899243-22-018465 · doc4.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,003

F1 · kind: These restricted stock units will be settled in common stock upon vesting.

F2 · shares: These restricted stock units shall vest in full on May 13, 2023.

F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0001209191-22-028699 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2032-05-10

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-22-028699 · doc4.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,875

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-21-071425 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,000

Underlying: Class A Common Stock · 260,000 shares

Expires 2031-12-22

F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 12/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Early Exercise is not permitted.

SEC source: 0001209191-21-055809 · doc4.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,400

F1 · shares: The shares of common stock are to be acquired upon the vesting of a restricted stock unit award granted to the Reporting Person. The restricted stock unit award shall vest as follows: vest over two years (vesting commencement date = September 1, 2021), with a one-year cliff as follows: on the first anniversary of the vesting commencement date, 50% of the restricted stock unit award shall vest, and on the second anniversary of the vesting commencement date, 50% of the restricted stock unit award shall vest. In total, 100% of the restricted stock unit award shall be vested on the second anniversary of the vesting commencement date.

SEC source: 0001203311-21-000032 · edgardoc.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,462

Underlying: Common Stock · 3,462 shares

Expires 2031-05-14

SEC source: 0001203311-21-000032 · edgardoc.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,500

F1 · security: These restricted stock units will be settled in common stock upon vesting.

F2 · date: These restricted stock units shall vest in full on May 14, 2022.

F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0001209191-21-033847 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2031-05-13

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · derivative.exercise_date: The equity award vests over a one year period.

SEC source: 0001209191-21-033847 · doc4.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,875

F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

F2 · shares: The equity award vests over a one year period.

SEC source: 0001209191-21-006340 · doc4.xml · derivative · entry 1

Orwin John A · CIK 0001477384 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,000

Underlying: Class A Common Stock · 260,000 shares

Expires 2031-01-26

F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

SEC source: 0001203311-20-000049 · edgardoc.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,171

Underlying: Common Stock · 3,171 shares

Expires 2030-05-15

SEC source: 0001203311-20-000049 · edgardoc.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,098

F1 · security: These restricted stock units will be settled in common stock upon vesting.

F2 · date: These restricted stock units shall vest in full on May 15, 2021.

F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

SEC source: 0001209191-20-030749 · doc4.xml · derivative · entry 2

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2030-05-14

SEC source: 0001209191-20-030749 · doc4.xml · nonDerivative · entry 1

Orwin John A · CIK 0001477384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,875